logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Agios Pharmaceuticals, Inc.


USPTO Granted Patents = 99

% Expired Patents = 22.2



Trademarks = 27

Forward Citations = 597

Loading Chart...
Loading Chart...

84 inventors (with patents filed for the assignee):

goldMedal Jeffrey O Saunders (31 out of 68 patents)

silverMedal Francesco Gerald Salituro (30 out of 184 patents)

bronzeMedal Jeremy Mark Travins (29 out of 52 patents)

4.  Janeta Popovici-Muller (27 out of 45 patents)

5.  Shunqi Yan (19 out of 27 patents)

6.  Zhenwei Cai (16 out of 20 patents)

7.  Giovanni Cianchetta (15 out of 21 patents)

8.  Shin-San Michael Su (14 out of 15 patents)

9.  Dawei Cui (13 out of 15 patents)

10.  Rene Marc Lemieux (13 out of 21 patents)

11.  Samuel V Agresta (11 out of 14 patents)

12.  Ding Zhou (10 out of 22 patents)

13.  Zenon D Konteatis (9 out of 15 patents)

14.  Zhihua Sui (9 out of 108 patents)

15.  Robert Zahler (7 out of 74 patents)


Core Competencies:
Pyruvate Kinase
Therapeutic Compounds
Cancer Treatment
Cell Proliferation
Combination Therapy
Cytochrome P450
IDH Mutants
Glutaminase Inhibitors
Piperazine Compounds
Metabolic Processes
Brain Tumors
Pharmaceutical Compositions

99 patents:

1. 12673961 - Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations (2026-07-07),
2. 12667087 - METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS (2026-06-30),
3. 12612381 - Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide (2026-04-28),
4. 12428376 - Therapeutic compounds and compositions (2025-09-30),
5. 12377093 - Pyruvate kinase activators for use in therapy (2025-08-05),
6. 12133853 - Pyruvate kinase activators for use in treating blood disorders (2024-11-05),
7. 11957680 - Pyruvate kinase activators for use in treating blood disorders (2024-04-16),
8. 11919915 - Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations (2024-03-05),
9. 11878049 - Mitapivat therapy and modulators of cytochrome P450 (2024-01-23),
10. 11872225 - Pyruvate kinase modulators and use thereof (2024-01-16),
11. 11866411 - Therapeutic compounds and compositions (2024-01-09),
12. 11793806 - Pyruvate kinase activators for use in therapy (2023-10-24),
13. RE49582 - Therapeutic compounds and compositions (2023-07-17),
14. 11590132 - Pyruvate kinase activators for use in treating blood disorders (2023-02-28),
15. 11464775 - Pyruvate kinase modulators and use thereof (2022-10-11),
Agios Pharmaceuticals is a biopharmaceutical company dedicated to improving the lives of patients with genetically defined diseases. They focus on developing potentially transformative medicines that target key metabolic pathways to stop and potentially reverse the progression of these diseases. Agios combines scientific leadership, deep clinical development expertise, and a commitment to patient care to bring innovative therapies to patients in need.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Agios Pharmaceuticals, Inc.
99 Patents

#29 in Cambridge, MA

#210 in Massachusetts

#3,821 in US

#7,841 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Agios Pharmaceuticals, Inc.

Forward Citations = 597

84 inventors:

goldMedal Jeffrey O Saunders (31 out of 68 patents)

silverMedal Francesco Gerald Salituro (30 out of 184 patents)

bronzeMedal Jeremy Mark Travins (29 out of 52 patents)

4.  Janeta Popovici-Muller (27 out of 45 patents)

5.  Shunqi Yan (19 out of 27 patents)

Please report any incorrect information to [email protected]
Loading…